Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 239

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 239
---
 and Financing Activities:                              |     |          |            |   |     |          |            |   |
| Convertible                                                                  
 note issued as a settlement of a previously accrued liability                |     | $        |          - |   |     | $        |    150,000 |   |
| Restricted                                                                   
 stock issued for forgiveness of salary                                       |     | $        |     10,000 |   |     | $        |  2,158,050 |   |
| Stock                                                                        
 options issued for forgiveness of salary                                     |     | $        |     50,000 |   |     | $        |  2,614,790 |   |
| Note                                                                         
 payable, related party assigned to Note payable                              |     | $        |    266,667 |   |     | $        |          - |   |
| Stock                                                                        
 issued for exercise of options in exchange for note payable, related parties |     | $        |          - |   |     | $        |    100,000 |   |
| Discount                                                                     
 on convertible note payable                                                  |     | $        |          - |   |     | $        |     60,000 |   |
| Stock issued for conversion of notes                                         |     | $        |    636,866 |   |     |          |            |   |

<div align='center'>The accompanying notes are an integral part of these financial statements</div>

| F-5 |

<div align='center'>JUPITER NEUROSCIENCES, INC.

NOTES TO FINANCIAL STATEMENTS

December 31, 2024 and 2023</div>

Note 1 – Organization and Description of Business

Jupiter Neurosciences, Inc. (the “Company”) is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company incorporated in Delaware in January 2016. The Company has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. The product candidate, called JOTROL, has many potential indications of use for rare diseases. We are primarily targeting Mucopolysaccharidoses Type 1, Friedreich’s Ataxia, and MELAS. In the larger disease areas, we are primarily targeting Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease.

On August 30, 2021, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the